Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma
| Autor: | Avivi, I., Canals, C., Vernant, J.P., Wulf, G., Nagler, A., Hermine, O., Petersen, E., Yakoub-Agha, I., Craddock, C., Schattenberg, A.V., Niederwieser, D., Thomson, K., Blaise, D., Attal, M., Pfreundschuh, M., Passweg, J., Russell, N., Dreger, P., Sureda, A. |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Oncology Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2] Graft vs Host Disease 0302 clinical medicine Recurrence immune system diseases hemic and lymphatic diseases Young adult Child Histocompatibility Testing Hematopoietic Stem Cell Transplantation Hematology Middle Aged 3. Good health surgical procedures operative Histocompatibility 030220 oncology & carcinogenesis Disease Progression Alemtuzumab Female Lymphoma Large B-Cell Diffuse Unrelated Donors medicine.drug Adult medicine.medical_specialty Allogeneic transplantation Adolescent Transplantation Autologous Young Adult 03 medical and health sciences Internal medicine medicine Humans Transplantation Homologous Aged Retrospective Studies Transplantation business.industry Siblings Retrospective cohort study medicine.disease Surgery Lymphoma Multivariate Analysis business Diffuse large B-cell lymphoma 030215 immunology |
| Zdroj: | Bone Marrow Transplantation, 49, 671-8 Bone Marrow Transplantation, 49, 5, pp. 671-8 |
| ISSN: | 0268-3369 |
| DOI: | 10.1038/bmt.2014.4 |
| Popis: | Item does not contain fulltext The objective of this retrospective analysis was to compare outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who received either a matched sibling (sib) or an unrelated donor (URD) allogeneic hematopoietic cell transplantation (allo-HCT). Long-term outcome of 172 DLBCL patients receiving URD-HCT between 2000 and 2007 and reported to the European Group for Blood and Marrow Transplantation, was compared with that of 301 subjects, allografted from sib-HCT. With a median follow-up of 45 months, 3-year PFS approached 35% for both groups; overall survival (OS) was 42% for sib-HCT versus 37% for URD (NS). Multivariate analyses confirmed that donor type was not associated with differences in non-relapse mortality (NRM), relapse rate (RR), PFS or OS. Poor performance status (PS) and refractory disease adversely affected PFS and OS. Prior auto-SCT and multiple previous therapies predicted for shorter PFS. NRM was adversely affected by older age (50 years), poor PS and refractory disease, and RR by time from diagnosis to allo-HCT of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|